Actym Therapeutics, Inc. — Form D
Actym Therapeutics, Inc. of BERKELEY, CA, a company, filed a Form D exempt-offering notice with the SEC on 2023-07-06. The offering totals $27.5M, of which $11.2M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-07-06
- Form: D
- Accession: 0001808722-23-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $27.5M
- Amount sold: $11.2M
- Remaining: $16.3M
- Investors: 5
- Date of first sale: 2023-06-28
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-486067
Issuer
- Name: Actym Therapeutics, Inc.
- CIK: 0001808722
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 626 BANCROFT WAY, BERKELEY, CA, 94710
- Phone: 5102567167
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Benjamin D Chen | Director | Berkeley, CA |
| Julie D Cherrington | Director | Berkeley, CA |
| Kanad D Das | Director | Berkeley, CA |
| Ron D Mazumder | Director | Berkeley, CA |
| Christopher D Thanos | Director | Berkeley, CA |
| Christopher D Thanos | Executive Officer | Berkeley, CA |
| Christopher D Thanos | Promoter | Berkeley, CA |
| Amit D Kumar | Director | Berkeley, CA |
| Amit D Kumar | Promoter | Berkeley, CA |
| James D Huang | Director | Berkeley, CA |
Other filings by this issuer (1)
More